Strengthening Laboratory Systems for MDRTB Strengthening Laboratory Systems for MDRTB John Ridderhof, DrPH Chair, Subgroup on Laboratory Capacity Strengthening Associate Director for Laboratory Science National Center for Prevention, Detection and Control of Infectious Diseases CCID/CDC John Ridderhof, DrPH Chair, Subgroup on Laboratory Capacity Strengthening Associate Director for Laboratory Science National Center for Prevention, Detection and Control of Infectious Diseases CCID/CDC
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Strengthening Laboratory
Systems for MDRTB
Strengthening Laboratory
Systems for MDRTBJohn Ridderhof, DrPH
Chair, Subgroup on Laboratory Capacity Strengthening
Associate Director for Laboratory Science
National Center for Prevention, Detection and Control of Infectious Diseases
CCID/CDC
John Ridderhof, DrPH
Chair, Subgroup on Laboratory Capacity Strengthening
Associate Director for Laboratory Science
National Center for Prevention, Detection and Control of Infectious Diseases
CCID/CDC
2
Current challenges/MDRCurrent challenges/MDR
• 5-10%% MDR cases diagnosed
• Difficulties in implementing culture and DST
• Quality of culture and DST is often questionable
• Second line drug (SLD) testing primarily
restricted to SRLs
• 5-10%% MDR cases diagnosed
• Difficulties in implementing culture and DST
• Quality of culture and DST is often questionable
• Second line drug (SLD) testing primarily
restricted to SRLs
3
Key MessagesKey Messages
• Strengthen microscopy and culture and implement new methods
• Better test performance in laboratories where quality systems are required
• Scale up of laboratory capacity will require initiatives to integrate services
• The laboratory is a system and new diagnostics will require strong systems
• Strengthen microscopy and culture and implement new methods
• Better test performance in laboratories where quality systems are required
• Scale up of laboratory capacity will require initiatives to integrate services
• The laboratory is a system and new diagnostics will require strong systems
4
Stop TB Partnership
Workgroups
Stop TB Partnership
Workgroups
• DOTS Expansion WG
� Subgroup on Laboratory Capacity Strengthening (SLCS)
• WG on New TB diagnostics
• TB/HIV WG
• MDRTB WG
• WG on New TB Drugs
• WG on New TB Vaccines
• Advocacy, Communication, and Social Mobilization WG
• DOTS Expansion WG
� Subgroup on Laboratory Capacity Strengthening (SLCS)
• WG on New TB diagnostics
• TB/HIV WG
• MDRTB WG
• WG on New TB Drugs
• WG on New TB Vaccines
• Advocacy, Communication, and Social Mobilization WG
5
Coordinating CentreAntwerp, Belgium
Network of 26 Supranational Laboratories
National/Regional Reference Laboratories
Panel of 30 coded isolates
Panel of 20 coded isolates
Sample of isolates for rechecking
(DRS/DOTS-Plus)
Initial Assessment
Ongoing TA
6
Acceleration of SLCS activitiesAcceleration of SLCS activities
• Formed in 2002, Initial focus on SRLN has evolved to general capacity building
• Development of technical guidance transitioned from volunteer efforts to structured consensus process with partners
• Core group formed, meetings in March and July 2007
• USAID funding for business plan development
• Increase in technical workgroups
• Formed in 2002, Initial focus on SRLN has evolved to general capacity building
• Development of technical guidance transitioned from volunteer efforts to structured consensus process with partners
• Core group formed, meetings in March and July 2007
The US initiative in the 90The US initiative in the 90’’s to meet the challenge of MDRs to meet the challenge of MDR--TBTB““The Laboratory Makes a DifferenceThe Laboratory Makes a Difference””
12
Required expansion of testing and fundingRequired expansion of testing and funding
2010 2012 2015
Required e
xpansion of
Culture capacity: fro
m 10 to 60
mln pa
# of tests required (mln) $ of funding
required (mln)
2500
2000
1500
1000
500
Required
expansi
on of Smear c
apacity
: from
80 to 20
0 mln p
a
To reach MDG targets, a global capacity gap of 120 mln smear and 50 mln culture tests must be addressed – in accordance to country-specific conditions and priorities. This requires $2,500 mln for investment funding, of which $900 mln is needed for urgent immediate requirements.
2008
Urg
en
t M
DG
Targ
et
200
150
100
50
13
Strengthening the Global TB Laboratory NetworkStrengthening the Global TB Laboratory Network
Network will be an active facilitator of communication and provide various global infrastructure services including guidance, assurance and interface connection activities – all synchronized to be a coherent network service.
Network will be an active facilitator of communication and provide various global infrastructure services including guidance, assurance and interface connection activities – all synchronized to be a coherent network service.
- organizing meetings- Advanced communication technologies
- TB-Wiki; Knowledge Resource Network online
Interface Connection:
- Matchmaking of projects between countries and implementing partners
- manage stakeholders- Advocacy for lab funding- Other TB communities- Other disease networks
Assurance activities:
- coordination of EQA- specifications for equipment and machines
- Global accreditation system- Monitoring/evaluation
Guidance Activities:- lab manuals- 2nd line DST- Creation of training materials
- Recommendations for funding strategy
- National Roadmap advice
Exemplary activities of the Network
14
Priority Activities at Global LevelPriority Activities at Global Level
• International training for 100 “implementation”consultants
• New strategies for knowledge sharing
• Drug resistance surveillance funding gap
• Equipment and material specifications
• Training materials for culture and DST
• Guidance for second line drug (SLD) testing
• Update laboratory manuals (WHO/IUATLD/CDC)
• Develop Accreditation for TB laboratories
• National “roadmaps” for countries/technical partner
• Office for coordination of Laboratory Technical Assistance
• International training for 100 “implementation”consultants
• New strategies for knowledge sharing
• Drug resistance surveillance funding gap
• Equipment and material specifications
• Training materials for culture and DST
• Guidance for second line drug (SLD) testing
• Update laboratory manuals (WHO/IUATLD/CDC)
• Develop Accreditation for TB laboratories
• National “roadmaps” for countries/technical partner
• Office for coordination of Laboratory Technical Assistance
15
Key points from planning processKey points from planning process
• Scale up of technical assistance (TA) through multiple partners requires greater coordination, different models of support, and increased tool development
• Network core will be housed in WHO with project management involving partners
• Increase senior and midlevel laboratory consultants
• Scale up of technical assistance (TA) through multiple partners requires greater coordination, different models of support, and increased tool development
• Network core will be housed in WHO with project management involving partners
• Increase senior and midlevel laboratory consultants
16
Next Steps/PrioritiesNext Steps/Priorities
• Refine business plan based on input from key StopTB stakeholders at Capetown
• Meet with multiple donors to seek sustained funding support
• Promote advocacy for laboratory programs/capacity building
• Promote partner participation/contributions through increased SLCS communications and coordination
• Refine business plan based on input from key StopTB stakeholders at Capetown
• Meet with multiple donors to seek sustained funding support
• Promote advocacy for laboratory programs/capacity building
• Promote partner participation/contributions through increased SLCS communications and coordination